Evidence map›Paper›PMID 40588510›Full record

ArticleActa pharmacologica Sinica2025

PYRCR alleviates myocardial ischemia/reperfusion injury in mice via inhibiting DRG2-mediated cardiomyocyte pyroptosis.

Xin-Zhe Chen, Hong-Fei Xu, Xue-Mei Zhao, Fu-Hai Li, Jia-Hao Ren, Lu-Yu Zhou, Cui-Yun Liu, Yu-Qin Wang, Su-Min Yang, Fang Liu and 3 more

Abstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xin-Zhe Chen *Department of Pathology, Binzhou Medical University Hospital, Binzhou, 256603, China.
Hong-Fei Xu *Department of Forensic Medicine, School of Basic Medical Sciences, Suzhou Medical College of Soochow University; Jiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, School of Basic Medical Sciences, Soochow University, Suzhou, 215123, China.
Xue-Mei Zhao *State Key Laboratory of Cardiovascular Disease, Heart Failure center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100037, China.
Fu-Hai Li *Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao, 266021, China.
Jia-Hao RenDepartment of Cardiovascular Surgery, Institute of Chronic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, 266021, China.
Lu-Yu ZhouDepartment of Cardiovascular Surgery, Institute of Chronic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, 266021, China.
Cui-Yun LiuDepartment of Cardiovascular Surgery, Institute of Chronic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, 266021, China.
Yu-Qin WangDepartment of Cardiovascular Surgery, Institute of Chronic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, 266021, China.
Su-Min YangDepartment of Cardiovascular Surgery, Institute of Chronic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, 266021, China.
Fang LiuCenter of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, and Department of Anatomy, Guilin Medical University, Guilin, 541004, China. fang.liu@msn.com.
Yu-Hui ZhangState Key Laboratory of Cardiovascular Disease, Heart Failure center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100037, China. zhangyhfw@163.com.
Kun WangDepartment of Cardiovascular Surgery, Institute of Chronic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, 266021, China. wangk696@qdu.edu.cn.
Xiang-Qian GaoDepartment of Pathology, Binzhou Medical University Hospital, Binzhou, 256603, China. xiangqiangao@bzmc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNAs) are a distinct class of endogenous RNAs characterized by their covalently closed circular structure. CircRNAs play crucial regulatory roles in various biological processes and pathogenesis. In this study we investigated the role of circRNAs in cardiomyocyte pyroptosis and underlying mechanisms. Ischemia/reperfusion (I/R)-induced myocardial injury was induced in mice by ligation of the left anterior descending coronary artery (LAD). Neonatal mouse cardiomyocytes were subjected to hypoxia/reoxygenation (H/R) assault. By using circRNA microarray, we found that the expression levels of a pyroptosis-related circRNA (designated PYRCR) were markedly decreased in H/R-exposed cardiomyocytes and I/R-injured mouse hearts. Overexpression of PYRCR inhibited cardiomyocyte pyroptosis, attenuated I/R-induced myocardial infarction and ameliorated cardiac function in mice. By RNA pull-down assays coupled with MS analysis followed by molecular validation, we identified developmental regulated GTP-binding protein 2 (DRG2) as the direct downstream target of PYRCR. Cardiac-specific DRG2 knockout mice displayed attenuated pyroptosis and enhanced cardiac function following I/R injury compared to DRG2

Indexed as

Myocardial Reperfusion InjuryMyocytes, CardiacPyroptosisRNA, CircularAnimalsCells, CulturedDynaminsMaleMiceMice, Inbred C57BLMice, KnockoutDnm1l protein, mouseDynaminsRNA, Circularcircular RNAsDRG2Drp1myocardial infarctionPYRCRpyroptosis

Identifiers

PMID40588510
PMCPMC12644509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.